Payment overview · 2025
General Payments
$859.10
34 reported records · 16 companies
Healthcare provider profile · identity verified
Dina Doolin, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NEW SMYRNA BEACH, FL · NPI 1356446223
Verified facts
What the public records show
CMS Open Payments records show Dina Doolin, D.O. received $859.10 in general payments during 2025 across 34 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $150.09 | 17.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $113.56 | 13.2% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $94.41 | 11.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $87.27 | 10.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.56 | 8.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.16 | 8.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.82 | 7.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.67 | 6.0% | 2 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $33.83 | 3.9% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $22.94 | 2.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.01 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.75 | 2.2% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $17.38 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.43 | 1.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.47 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.75 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $841.72 | 33 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $150.09 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $94.41 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $91.94 | 5 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $87.27 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.74 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $69.16 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $69.16 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.82 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.28 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.28 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 122 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 629 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 129 |
| Losartan Potassium | Losartan Potassium | 382 | 115 |
| Atorvastatin Calcium | Atorvastatin Calcium | 356 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 92 |
| Omeprazole | Omeprazole | 302 | 101 |
| Tramadol Hcl | Tramadol Hcl | 292 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 86 |
| Methylprednisolone | Methylprednisolone | 253 | 160 |
| Alprazolam | Alprazolam | 246 | 70 |
| Lisinopril | Lisinopril | 214 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 65 |
| Gabapentin | Gabapentin | 177 | 62 |
| Azithromycin | Azithromycin | 166 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 51 |
| Montelukast Sodium | Montelukast Sodium | 161 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 155 | 59 |
| Lorazepam | Lorazepam | 152 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 46 |
| Metformin Hcl | Metformin Hcl | 131 | 40 |
| Alendronate Sodium | Alendronate Sodium | 126 | 34 |
| Trazodone Hcl | Trazodone Hcl | 125 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 33 |
| Eliquis | Apixaban | 122 | 34 |
| Simvastatin | Simvastatin | 119 | 36 |
| Sertraline Hcl | Sertraline Hcl | 117 | 35 |
| Famotidine | Famotidine | 111 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 103 | 38 |
| Meloxicam | Meloxicam | 94 | 34 |
| Potassium Chloride | Potassium Chloride | 90 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 28 |
| Temazepam | Temazepam | 87 | 18 |
| Furosemide | Furosemide | 86 | 34 |
| Clonazepam | Clonazepam | 84 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 20 |
| Diazepam | Diazepam | 83 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 74 | 69 |
| Ondansetron Odt | Ondansetron | 73 | 38 |
| Valacyclovir | Valacyclovir Hcl | 72 | 36 |
| Bupropion Xl | Bupropion Hcl | 68 | 24 |
| Ibuprofen | Ibuprofen | 68 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 24 |
| Allopurinol | Allopurinol | 65 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 51 |
| Prednisone | Prednisone | 63 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 16 |
| Valsartan | Valsartan | 54 | 16 |
| Atenolol | Atenolol | 53 | 17 |
| Glipizide | Glipizide | 53 | 15 |
| Fenofibrate | Fenofibrate | 52 | 15 |
| Ozempic | Semaglutide | 52 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 12 |
| Carvedilol | Carvedilol | 49 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 48 | 24 |
| Estradiol | Estradiol | 47 | 16 |
| Ezetimibe | Ezetimibe | 46 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 44 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 11 |
| Mupirocin | Mupirocin | 43 | 35 |
| Spironolactone | Spironolactone | 43 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Carisoprodol | Carisoprodol | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | 15 |
| Cephalexin | Cephalexin | 36 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Lovastatin | Lovastatin | 36 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 18 |
| Fluconazole | Fluconazole | 33 | 27 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 19 |
| Donepezil Hcl | Donepezil Hcl | 30 | 11 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 19 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 26 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 13 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | 11 |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ciclopirox | Ciclopirox | 17 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Cilostazol | Cilostazol | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $859.10 · 34 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, Auvelity, Brinsupri, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, GIMOTI, Indigo System, Kerendia, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, WATCHMAN FLX, Wegovy, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error